Navigation Links
Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis

Recently the Food and Drug Administration (FDA) issued a public health advisory to inform patients and health care // providers about the suspended marketing of Tysabri (nataluzimab) the drug meant to treat relapsing forms of multiple sclerosis (MS) which was approved by the FDA in 2004.

FDA supports the decision to voluntarily suspend marketing of the drug as well as the use of the product in clinical trials. However, it is believed that the drug has a promising role to play in treating multiple sclerosis.

Patients being treated with Tysabri have been asked to contact their physician to discuss appropriate alternative treatments while the reports are being evaluated.

A single fatality and one possible case of progressive Multifocal leukoencephalopathy (PML) have been reported in patients receiving Tysabri for MS. However, this adverse effect was not reported when trials were conducted before the marketing phase. Post-marketing studies have facilitated the rapid reporting and response to this new information.

Because Tysabri was just recently approved, these patients have only received at most a few doses of Tysabri and the FDA says it will maintain a close contact with the company during the process to study the relationship between Tysabri and the two serious adverse events.


'"/>




Page: 1

Related medicine news :

1. Early Warning System For Breast Cancer
2. Warning on radiowave exposure
3. A Seizure Late In Life Could be A Stroke Warning
4. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
5. Early Warning Signs Of Heart Disease
6. Warning issued by FDA over "Liqiang 4 Capsules"
7. Warning Signs On Powered Baby Milk
8. People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings
9. Global Outbreak Of Bird Flu Warning By Chinese Scientist
10. Experts Building Bird Flu Warning System
11. A Warning For Western Diet Followers!
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: